Invert Graphite Limited has released a press release.
Shareholder communication - clinical trial update
Filed with ASX ·
6ix hasn’t read this filing yet.
Invert Graphite Limited on 6ix
Earlier from Invert Graphite
- Appendix 4E and Full Year Statutory Accounts
- Appendix 4C - quarterly
- Appointment of Dr. Rosalind Wilson as CEO
- Appendix 4C
- Phase II clinical trial progress update
Later from Invert Graphite
- Appendix 4C for the September Quarter
- 50% recruitment reached in VF00102 Clinical Trial
- Factor receives $3.1M R&D tax rebate
- Shareholder Update
- Appendix 4C - December 2017 Quarter
Follow Invert Graphite into a list and get an email when it puts out news.
Follow Invert Graphite